Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 19, 2019

View Archived Issues

CJ-15314: a novel JAK1 inhibitor for the treatment of rheumatoid arthritis

A-166, a new anti-HER2 antibody-drug conjugate for advanced/metastatic solid tumors: phase I results

Lineage Cell Therapeutics provides update on phase I/IIa SCiStar study of OPC-1

Interim analysis of phase II data for licogliflozin in NASH

Preliminary phase I data presented for DCC-3014

Phase IIa data for IONIS-HBVRx in treatment-naive chronic HBV patients

STAT3-targeting PROTAC proof of principle for 'undruggables'

Novel PDX mouse models of gastric cancer

Effluent DcR2 is a new marker of peritoneal fibrosis in patients with peritoneal dialysis

Differentially expressed sncRNAs in patients with T1D at risk of progressive renal disease

Promising phase I/Ib data presented for the novel anti-CD73 antibody CPI-006

First placebo-controlled trial in renal scleroderma shows positive results for zibotentan

Fujifilm initiates phase I trial of FF-10850 in advanced solid tumors

Double-duty CD4+ T cells may hold key to longevity

3SBio and Verseau select VTX-0811 as first licensed program under immuno-oncology partnership

Phase II study of KarXT for acute psychosis in schizophrenia meets primary endpoint

Clinical study of [131I]omburtamab advances in desmoplastic small round cell tumors

A placebo-controlled, first-in-human phase I study of the anti-ADAMTS-5 nanobody M-6495

Janssen Pharmaceutica patents androgen receptor antagonists

Bristol-Myers Squibb divulges TLR7 agonists

Ribon Therapeutics describes TIPARP inhibitors

Landsteiner Genmed identifies CAPN1 inhibitors

Merck & Co. divulges nicotinic acetylcholine alpha7 receptor PAMs

U.K. clearance for phase I/II study of TX-200 in kidney transplantation

BioArctic to end SC-0806 development in complete spinal cord injury based on interim phase I/II data

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...